Vanguard Group
CLDI icon

Vanguard Group’s Calidi Biotherapeutics CLDI Stock Holding History

Vanguard Group’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$40.6K Hold
34,728
– – ﹤0.01% 4265
2025
Q3 		$52.8K Buy
34,728
+5,280
+18% +$22.4K ﹤0.01% 4295
2025
Q2 		$81.3K Hold
29,448
– – ﹤0.01% 4157
2025
Q1 		$200K Buy
29,448
+24,333
+476% +$277K ﹤0.01% 4076
2024
Q4 		$70.6K Buy
+5,115
New +$95.9K ﹤0.01% 4189
2024
Q3 		– Sell
-124
Closed -$2.99K – 4353
2024
Q2 		$2.99K Hold
124
– – ﹤0.01% 4413
2024
Q1 		$8.44K Buy
124
+20
+19% +$2.04K ﹤0.01% 4433
2023
Q4 		$18.8K Buy
+104
New +$27.9K ﹤0.01% 4449

Other funds holding CLDI

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Vanguard Group's CLDI Position: Q4 2025 in Review

Vanguard Group held its Calidi Biotherapeutics (CLDI) position steady in Q4 2025 at 34,728 shares worth $40.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4265.

Vanguard Group first reported a position in CLDI in Q4 2023 and has held it in 8 quarters since. The position peaked at $200K in Q1 2025. 27 funds tracked by Wall St. Rank hold CLDI as of Q4 2025.

  • Vanguard Group held 34,728 shares of Calidi Biotherapeutics worth $40.6K as of Q4 2025.
  • Vanguard Group left its Calidi Biotherapeutics share count unchanged in Q4 2025.
  • Calidi Biotherapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4265 holding.
  • Vanguard Group first reported a position in Calidi Biotherapeutics in Q4 2023 and has held it in 8 quarters since.
  • Vanguard Group's Calidi Biotherapeutics position peaked at $200K in Q1 2025.
  • 27 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.